Interview

Page of ( Articles)

Mark Glover: The tech opportunity for clinical trials November 14, 2019
Medidata's Mark Glover told BiotechDispatch the technology-focused clinical research organisation is developing options like the 'synthetic control arm' to address the challenge of recruiting patients for trials targeting rare diseases.
Dr John Bashford: Redefining the future for rare cancers July 9, 2019
Dr John Bashford, research director at the Icon Group, spoke with BiotechDispatch about its approach to cancer care and clinical trials using targeted therapy and immunotherapy.
'Extending' the 'promise of immunotherapy' March 21, 2019
MSD invests almost $400 million every year in Australian clinical trials, the majority involving PBS-listed immunotherapy KEYTRUDA, according to the company's Dr Bilal Piperdi.
'Our current concept of aging is wrong' March 12, 2019
Two Australians are at the helm of a US-based company looking to revolutionise the health system's approach to and treatment of aging.
New testing means patients no longer 'defined by their symptoms' February 28, 2019
AbbVie's head of global head of immunology discovery research says the ability to profile patients at the molecular level has the potential to dramatically change treatment for people living with chronic conditions.
AusBiotech CEO Lorraine Chiroiu on early impressions and future priorities September 3, 2018
Recently appointed CEO of AusBiotech, Lorraine Chiroiu, says the association plans to build its role in policy to help ensure the operating environment supports the continued growth of the sector.
Driven by the 'profound unmet needs of patients' August 7, 2018
Biogen's global chief medical officer told BiotechDispatch the company is undaunted by the historically high failure rates in the development of treatments for Alzheimer’s.
A 'disruptive technology' that 'changed everything' June 26, 2018
Whole genome sequencing is already changing healthcare systems and treatments, according to Dr Howard Jacob, vice president and head of genomic research at AbbVie.
Value-based healthcare 'inevitable' April 12, 2018
A move to value-based healthcare is inevitable, says the global CEO of Medtronic Omar Ishrak. Mr Ishrak spoke with BiotechDispatch during a recent trip to Australia....
New research centre in Queensland October 18, 2016
The University of Queensland has launched a new $7 million regenerative medicine research centre with the aim of improving the quality of life of senior Australians. Queensland Premier...
Australia must do more to build 'true innovation eco-system' May 30, 2016
Teva Pharma is the world's largest generics company but there is much more to Teva in Australia, according to managing director John Michailidis. Mr Michailidis was appointed to lead...
'A match made in heaven' May 25, 2016
Industry has had to change its approach to innovation as the world becomes more inter-connected, according to Seema Kumar, Vice President, Innovation, Global Health, and Policy Communication,...

Page of ( Articles)

Interview

Most Read

More biotech companies moving into ASX 200

European approval for Starpharma's VivaGel condom

Imugene appoints world-renowned surgeon to advisory board

Australian company Noxopharm updates on pipeline

Antisense completes dosing in phase two ATL1102 trial

New Stories

Australian company Noxopharm updates on pipeline

European approval for Starpharma's VivaGel condom

Imugene appoints world-renowned surgeon to advisory board

More biotech companies moving into ASX 200

Antisense completes dosing in phase two ATL1102 trial

Antisense Therapeutics announces presentation of additional ATL1102 data

Cochlear confirms FDA clearance for Osia 2 System

Sign In

Most Read

More biotech companies moving into ASX 200

European approval for Starpharma's VivaGel condom

Imugene appoints world-renowned surgeon to advisory board

Australian company Noxopharm updates on pipeline

Antisense completes dosing in phase two ATL1102 trial

Follow Us

New Stories

Australian company Noxopharm updates on pipeline

European approval for Starpharma's VivaGel condom

Imugene appoints world-renowned surgeon to advisory board

More biotech companies moving into ASX 200

Antisense completes dosing in phase two ATL1102 trial

Antisense Therapeutics announces presentation of additional ATL1102 data

Cochlear confirms FDA clearance for Osia 2 System